 MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for immune-response modulation for treating cancer. MacroGenicss pipeline consists of 7 therapeutics with all 7 in clinical phases covering various cancers with Margetuximab, the lead candidate, filing for approval PDUFA date Dec. 18th, 2020. 